Audentes Therapeutics (BOLD) Tops Q3 EPS by 7c

Audentes Therapeutics (NASDAQ: BOLD) reported Q3 EPS of ($1.00), $0.07 better than the analyst estimate of ($1.07).

Strong balance sheet with September 30, 2019 cash, cash equivalents and marketable securities of $351.5 million

For earnings history and earnings-related data on Audentes Therapeutics (BOLD) click here.

You May Also Be Interested In

• Wolfe upgrades AT&T to Outperform as improving fundamentals outweigh Starlink risk
• First Mid Bancshares, Inc. (FMBH) Tops Q2 EPS by 24c
• Freeport-McMoran (FCX) Tops Q2 EPS by 15c